Dermatology Times Staff

A glimpse at what to expect from Dermatology Times this week.

Top educators in dermatology will come together to deliver CME lectures and engaging panel discussions via a premiere virtual platform. Learn more about MauiDerm Connect coming September 23-27.

In this webinar, moderated by Daniel Siegel, M.D., M.A., FAAD, FACMS, experts discuss guidance on the use of teledermatology and ways to successfully implement new models of care during the COVID-19 pandemic.

A middle-aged male patient with a superficial lesion on right upper back.

Read the highlights from our February 2020 issue in the slideshow below.

View the highlights from our January 2020 issue in this slideshow.

In this slideshow, review the advancements, changes and trends that shaped dermatology in 2019.

From plasma energy to CBD in skincare, these are a few of the hot topics the Dermatology Times team covered in 2019 that are worthy of keeping an eye on in 2020.

To recognize Antibiotic Awareness Week, we’ve gathered articles on antibiotic use in acne, alternative therapies and treatment trends in the specialty. View the highlights in this slideshow.

In this interview, Dr. Anna De Benedetto discusses what initially drew her to dermatology and what inspired her to study atopic dermatitis in the elderly.

To recognize the one year anniversary of our Innovation column, the Dermatology Times Staff has compiled key takeaways from topics covered throughout the year. View them in this slideshow.

Refresh your memory on treatment guidelines for mild, moderate and severe acne in this easy-to-view slideshow.

LEO Pharma has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for the study of an oral atopic dermatitis treatment, JW1601/LP0190, according to a company announcement. 

Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Federal Drug Administration (FDA) for its novel acne treatment, clascoterone cream 1%, according to a company announcement released today.

The U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for Ortho Dermatologics’ novel tazarotene O.045% lotion (IDP-123) with a PDUFA action date of Dec. 22, 2019, according a recent announcement from the company.

In this on-going article, we plan to highlight new skincare products as they are released. Bookmark this page to stay up-to-date as we will update it every month.

In this table, we highlight how psoriasis treatments have evolved over the past four decades. 

Some chemicals in over-the-counter sunscreens may impair marine life, says the National Ocean Service. As a result, they are recommending people choose sunscreens without these chemicals ingredients.

Crisaborole ointment, 2%, (Eucrisa, Pfizer) appears to be safe and effective in children aged three months to less than 24 months who have mild-to-moderate atopic dermatitis, according to results of a phase 4 trial released yesterday.

Ortho Dermatologics announced that halobetasol propionate and tazarotene lotion, 0.01%/0.045% (Duobrii, Ortho Dermatologics) is now commercially available to healthcare providers, according to a press release issued June 25.

New muscle-toning technology treats abdomen, buttocks, thighs.

Because a patient’s atopic dermatitis may also have a profound effect on parental caregivers, clinicians should seek to make an assessment of parental emotional and psychosocial well-being, and offer patient educational materials to help bring awareness to the issue.

Earlier this year, Galderma announced a new multi-disciplinary group of advisory members that compose The Women in Aesthetics Leadership Council. In this article, Dermatology Times acknowledges and congratulates the women on the advisory board who fall under the dermatology specialty.

Are your patients are looking for alternatives to surgery for non-melanoma skin cancer? Superficial radiation therapy (SRT) may be the answer.

Young African American patients with psoriasis are at a higher risk of atherosclerotic cardiovascular disease (ASCVD) and traditional cardiovascular risk factors than white patients with psoriasis of the same age group, says a recent study.